MDxHealth SA (NASDAQ:MDXH) Short Interest Up 133.8% in February

MDxHealth SA (NASDAQ:MDXH) saw a significant increase in short interest in the month of February. As of February 28th, there was short interest totalling 31,100 shares, an increase of 133.8% from the February 13th total of 13,300 shares. Based on an average daily volume of 113,500 shares, the short-interest ratio is currently 0.3 days. Approximately 0.2% of the company’s shares are short sold.

Hedge Funds Weigh In On MDxHealth

A number of institutional investors have recently bought and sold shares of the stock. AWM Investment Company Inc. raised its stake in MDxHealth by 11.1% in the fourth quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company’s stock worth $11,189,000 after buying an additional 471,290 shares in the last quarter. Delta Investment Management LLC bought a new position in MDxHealth in the fourth quarter worth about $81,000. FAS Wealth Partners Inc. raised its stake in MDxHealth by 49.6% in the fourth quarter. FAS Wealth Partners Inc. now owns 24,425 shares of the company’s stock worth $58,000 after buying an additional 8,100 shares in the last quarter. Northern Trust Corp bought a new position in MDxHealth in the fourth quarter worth about $1,033,000. Finally, Northern Right Capital Management L.P. bought a new position in MDxHealth in the fourth quarter worth about $246,000.

MDxHealth Stock Performance

MDxHealth stock opened at $1.50 on Friday. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14. The firm has a 50-day moving average of $1.89 and a 200-day moving average of $2.10. The firm has a market cap of $70.93 million, a P/E ratio of -0.99 and a beta of 1.37. MDxHealth has a 1-year low of $1.35 and a 1-year high of $3.50.

MDxHealth (NASDAQ:MDXH) last posted its earnings results on Wednesday, February 26th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. The company had revenue of $24.74 million during the quarter, compared to analyst estimates of $22.67 million. Sell-side analysts expect that MDxHealth will post -1.15 EPS for the current year.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.